Qynapse
About Qynapse
Qynapse is a medical technology company leveraging artificial intelligence (AI) to advance neuroimaging for Central Nervous System (CNS) disorders. Their flagship product, QyScore®, is an FDA-Cleared and CE-Marked neuroimaging software platform designed for physicians. It provides automated, quantitative measures of neuroinflammation and neurodegeneration from brain MRI scans. This supports more accurate and timely diagnosis, facilitates disease and therapy monitoring, and aids in developing tailored treatment plans in routine clinical practice.
Beyond clinical care, QyScore® is also utilized in clinical trial settings to enhance precision by reducing image reading variability, improving patient pre-identification for trials, automating image processing and analysis, and potentially offering better measurement of drug efficacy and safety. Qynapse is also developing QyPredict®, a research-use-only platform powered by machine learning algorithms. QyPredict® aims to predict individual patient disease trajectories, which could transform and improve timely intervention and treatment plans, and enhance targeted patient selection in clinical trials. The company’s solutions are focused on providing objective and data-driven insights for conditions such as Alzheimer’s disease, Multiple Sclerosis, and Parkinson’s disease.
Focus Areas
Business Intelligence
| Key Investors | PariSanté Campus, ballas invest, Agoranov, Wilco(Paris), GO Capital |
| Partnerships | Calyx, University of Miami Miller School of Medicine, AG Mednet |
| Acquisitions | True Positive Medical Devices (2020) |
| Technology | AI-powered neuroimaging software platform, cloud-based |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
For physicians, Qynapse's solutions offer empowering, illuminating, and objective data that can significantly enhance clinical decision-making. QyScoreu00ae provides precise, accurate, and reliable readouts, reducing the likelihood of misdiagnosis and supporting timely interventions and tailored treatment plans. The automated patient reports and proprietary 3D visualization platform facilitate easier review and interpretation of complex MRI data. By standardizing image analysis and eliminating inter- and intra-rater variability, Qynapse helps ensure consistent and trustworthy results, ultimately leading to improved patient outcomes and a more personalized approach to long-term care. The cloud-based, easy-to-use platform is designed to scale with patient load, making it a practical tool for both routine clinical practice and research settings.
Qynapse's QyScoreu00ae platform is designed for seamless integration into existing hospital workflows. It is compatible with standard reading environments such as PACS, AV, and AI viewers. The platform supports input from 1.5T and 3T MRI scanners for T1 and T2FLAIR processing and can output results in various formats including DICOM, PDF, and CSV, facilitating data exchange and compatibility within diverse clinical and research infrastructures.
What the Web Says
Qynapse is a medical technology company that specializes in AI-powered neuroimaging analysis for central nervous system (CNS) disorders, such as Alzheimer's, Multiple Sclerosis, and Parkinson's disease. Their flagship product, QyScoreu00ae, is an FDA-cleared and CE-marked software platform that provides automated, high-resolution segmentation of brain structures from MRI scans. The company also offers QyPredictu00ae, a research-use-only platform that utilizes QyScoreu00ae outputs to identify patients likely to experience clinical decline. While there is substantial information about their products and their scientific backing, publicly available independent reviews from platforms like G2, Glassdoor, Capterra, or Reddit are limited.
Overall: PositiveStrengths
- QyScoreu00ae offers precise, automated, and accurate data-driven imaging analysis for personalized clinical support.
- The platform has the potential to improve the accuracy of diagnosis and monitoring for CNS diseases.
- QyScoreu00ae decreases image reading variability and segmentation errors by 89%.
- It has demonstrated better performance compared to certain other state-of-the-art automated methods on the market.
- QyPredictu00ae has shown promise in accurately identifying patients with preclinical Alzheimer's disease and mild cognitive impairment who are likely to experience cognitive decline.
- The platform is cloud-based, easy to use, and integrates seamlessly with existing clinical workflows.
Limitations
- Limited publicly available independent reviews from platforms like G2, Glassdoor, Capterra, and Reddit.
- Specific employer reviews regarding company culture, salaries, or work-life balance are not readily available.
- Lack of detailed user feedback on the day-to-day experience of using Qynapse products outside of company-provided testimonials.
Based on reviews from: Qynapse Official Website, AuntMinnie, PR Newswire, MedicalExpo
Last updated: 2026-07-20
Videos
News, demos, and interviews about Qynapse.
Videos load interactively. If none appear, search YouTube for Qynapse →
Press & Coverage
Frequently Asked Questions
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]